This acceptance marks the fifth major medical conference this year to feature bexmarilimab in an oral session, reinforcing the drug's unique mechanism in hematologic malignancies and potential to ...
NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...
SYDNEY, AUSTRALIA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...
The ESMO Gastrointestinal Cancers Congress to be held July 2-5 in Barcelona ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the "Company”), a U.S.-based, global biotech ...
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific ...
FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (TERN), a clinical stage oncology company, today announced that data from the ongoing CARDINAL trial of TERN-701, a ...
Atacicept is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the ...
Informal Providers—Ground Realities in South Asian Association for Regional Cooperation Nations: Toward Better Cancer Primary Care: A Narrative Review Hidden oral cancer sites and residence in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback